The muscle relaxant that doctors and pharmacists increasingly flag as overused in back pain is cyclobenzaprine, sold under the brand name Flexeril. Despite being one of the most commonly dispensed medications in the United States, a growing body of research — including a landmark 2024 systematic review in JAMA Network Open — found that muscle relaxants do not appear beneficial for low back pain when used beyond the first few days. For the millions of Americans who leave an emergency room or primary care office with a prescription for cyclobenzaprine, the evidence suggests they are taking on real side effects for marginal, short-lived relief. Consider a 55-year-old woman with chronic lower back pain who has been refilling her cyclobenzaprine prescription for six months: the research shows the drug likely stopped offering meaningful benefit after the first four days, while the sedation and dry mouth she experiences every evening are not going away.
This matters beyond orthopedics, and it matters especially for brain health. Cyclobenzaprine and several other muscle relaxants carry anticholinergic properties — meaning they block acetylcholine, a neurotransmitter essential for memory and cognition. For older adults already at risk for cognitive decline or dementia, chronic use of these medications introduces a pharmacological burden on the brain that many clinicians now consider unacceptable given the weak evidence of benefit. This article examines how widespread muscle relaxant prescribing has become, what the latest clinical evidence actually says about their effectiveness, the specific risks they pose to brain health, and what alternatives patients and caregivers should discuss with their doctors.
Table of Contents
- Why Are Muscle Relaxants So Overprescribed for Back Pain?
- What Does the Latest Research Say About Cyclobenzaprine’s Effectiveness?
- The Cognitive Risks That Make This a Brain Health Issue
- How Muscle Relaxants Compare — and Why Some Are More Dangerous Than Others
- The Deprescribing Problem — Why Patients Stay on These Drugs Too Long
- What Works Instead of Muscle Relaxants for Back Pain
- Where the Evidence Is Heading
- Conclusion
- Frequently Asked Questions
Why Are Muscle Relaxants So Overprescribed for Back Pain?
The numbers paint a stark picture of how normalized these prescriptions have become. Skeletal muscle relaxants are prescribed to over 43 percent of patients with musculoskeletal back pain in emergency departments, according to data from the National Hospital Ambulatory Medical Care Survey spanning 2007 to 2019. In 2017, five muscle relaxants — cyclobenzaprine, diazepam, tizanidine, baclofen, and carisoprodol — all appeared on the top 200 most dispensed medications list in the United States. These are not niche drugs. They are part of the standard toolkit that many physicians reach for when a patient presents with back pain, even though the supporting evidence for their use, despite nearly 50 years of clinical history, remains what Cochrane reviewers classify as low certainty. Part of the problem is momentum. Cyclobenzaprine was approved decades ago, and generations of physicians trained during an era when the reflexive approach to back pain was rest, a muscle relaxant, and maybe a painkiller.
Prescribing habits are notoriously slow to change even when evidence shifts. Data from British Columbia shows that cyclobenzaprine is routinely prescribed at higher doses and for longer durations than recommended, frequently for unapproved long-term use. Compare this to a drug like an antibiotic, where stewardship programs have successfully shortened unnecessary courses — no equivalent pressure has existed for muscle relaxants until very recently. The American Academy of Family Physicians stated plainly in 2022 that evidence of benefit is lacking for low back pain relief with muscle relaxants. That is not a hedged or qualified statement. Yet prescribing continues at high rates, driven by patient expectations, time-pressured clinical encounters, and the absence of a simple pharmacological alternative that feels like “doing something.” For a patient in acute distress, writing a prescription takes thirty seconds. Explaining why physical therapy and time are better options takes considerably longer.
What Does the Latest Research Say About Cyclobenzaprine’s Effectiveness?
The most comprehensive recent assessment came from a 2024 systematic review published in JAMA Network Open, which analyzed 44 studies involving 2,482 participants. The findings were unambiguous: muscle relaxants do not appear beneficial for low back pain, fibromyalgia, or headaches when used long-term. The review did find that these drugs may help with trigeminal neuralgia, painful cramps, and neck pain — conditions that are distinct from the garden-variety low back pain for which cyclobenzaprine is most commonly prescribed. An earlier meta-analysis in JAMA Internal Medicine zeroed in on cyclobenzaprine specifically and found that its benefit is modest and greatest only in the first four days of treatment. after that narrow window, the drug’s pain-relieving advantage over placebo largely evaporates.
A 2025 systematic review in the European Spine Journal confirmed that while non-benzodiazepine muscle relaxants show some short-term benefit for acute low back pain, safety concerns are significant enough to warrant caution. None of the muscle relaxants studied produced what researchers call a clinically important difference over placebo — meaning that even when a statistical benefit exists, patients would not necessarily notice the difference. However, if someone is in the first 48 to 72 hours of an acute back spasm — the kind where they cannot straighten up or get out of bed — a short course of cyclobenzaprine might still have a role. The Mayo Clinic recommends it for short-term use of two to three weeks alongside rest and physical therapy. The problem is not that cyclobenzaprine is useless in every scenario. The problem is that it is prescribed far beyond those narrow circumstances, often refilled for months or years without reassessment, and given to patients with chronic pain where it offers no demonstrated benefit.
The Cognitive Risks That Make This a Brain Health Issue
Cyclobenzaprine is structurally similar to tricyclic antidepressants and shares their anticholinergic activity. Anticholinergic drugs block acetylcholine, the neurotransmitter most directly linked to memory formation and cognitive processing. For a 70-year-old taking cyclobenzaprine nightly for back pain, this means the drug is actively suppressing a chemical messenger that the aging brain already produces in diminishing quantities. Research over the past decade has consistently linked cumulative anticholinergic exposure to increased risk of cognitive impairment and dementia, particularly in older adults. The side effect profile of cyclobenzaprine reflects this pharmacology. In clinical trials, 53 percent of patients on cyclobenzaprine experienced at least one adverse effect compared to 28 percent on placebo — nearly double the rate. The most common complaints were drowsiness, dry mouth, and dizziness, all of which are hallmarks of anticholinergic burden.
The 2025 European Spine Journal review confirmed that central nervous system side effects are significantly more frequent with muscle relaxants compared to placebo. For an older adult, drowsiness does not merely mean feeling sleepy. It means impaired balance, increased fall risk, and the kind of mental fog that can be mistaken for — or can accelerate — early cognitive decline. For caregivers of someone living with dementia or mild cognitive impairment, this should be a red flag in any medication review. A muscle relaxant prescribed by an orthopedist or emergency physician may be quietly undermining the cognitive gains achieved through other interventions. The 2024 JAMA review specifically recommended that clinicians consider deprescribing muscle relaxants if pain-related goals are not being met, rather than continuing these medications indefinitely. That recommendation takes on particular urgency for anyone with existing cognitive vulnerability.
How Muscle Relaxants Compare — and Why Some Are More Dangerous Than Others
Not all muscle relaxants carry the same risk profile, and understanding the differences matters for making informed decisions. Cyclobenzaprine is the most commonly prescribed, but carisoprodol — sold as Soma — was reclassified as a Schedule IV controlled substance by the DEA in 2012 due to documented abuse and dependency concerns. Carisoprodol metabolizes into meprobamate, a barbiturate-like compound, which explains its potential for physical dependence and its popularity as a drug of abuse. When muscle relaxants are combined with opioids, the danger escalates sharply. Research published in StatPearls shows that baclofen carries the highest overdose hazard ratio at 2.52 when taken alongside opioids, compared to cyclobenzaprine as the reference. Carisoprodol had a hazard ratio of 1.64.
For an older adult who might also be taking an opioid following surgery or for chronic pain, the addition of a muscle relaxant introduces compounding sedation, respiratory depression risk, and cognitive impairment. This is not a theoretical concern — it is a pattern that pharmacists and emergency physicians encounter regularly. The tradeoff that patients and families should understand is straightforward. For acute, severe muscle spasm, a two-to-three-day course of cyclobenzaprine may offer modest relief that justifies the temporary sedation. For chronic back pain, the evidence says the risks — cognitive dulling, falls, drug interactions, dependency potential — outweigh benefits that are statistically indistinguishable from a sugar pill. Tizanidine and baclofen have their own specific indications, primarily for spasticity related to neurological conditions like multiple sclerosis, and should not be conflated with cyclobenzaprine in the back pain conversation.
The Deprescribing Problem — Why Patients Stay on These Drugs Too Long
The 2024 JAMA Network Open review made a recommendation that sounds simple but proves difficult in practice: clinicians should deprescribe muscle relaxants if pain-related goals are not met. Deprescribing — the structured process of tapering or stopping medications that are no longer beneficial — runs into several obstacles. Patients who have been taking cyclobenzaprine for months or years often believe it is helping, even when the evidence suggests otherwise. The sedating effect can feel like relief, particularly at bedtime, and stopping the medication may temporarily worsen sleep, which patients interpret as proof that the drug was working. Physicians face their own barriers. Revisiting a prescription initiated by another provider takes time and can feel confrontational.
An emergency physician who prescribed cyclobenzaprine for an acute episode may never see that patient again, while the primary care physician who inherits the prescription may not realize it was intended for short-term use. The result is therapeutic inertia — the drug stays on the medication list not because anyone actively decided it should, but because nobody actively decided it should not. In British Columbia, researchers documented this exact pattern: cyclobenzaprine prescribed at higher doses and for longer durations than guidelines recommend, with no clear clinical rationale for continuation. For families and caregivers managing the health of an older adult, particularly one with cognitive concerns, a medication review that specifically questions each muscle relaxant is essential. Ask why it was originally prescribed, whether the condition it targeted has resolved, and whether non-pharmacological alternatives have been adequately tried. The anticholinergic burden of a single drug might seem modest, but it compounds with other medications that share this property — certain antihistamines, bladder medications, and antidepressants all contribute to the same cumulative cognitive load.
What Works Instead of Muscle Relaxants for Back Pain
Physical therapy remains the intervention with the strongest evidence base for both acute and chronic low back pain, and it carries none of the cognitive risks associated with muscle relaxants. A physical therapist can identify specific movement patterns contributing to pain, prescribe targeted exercises, and use manual techniques that address the actual source of muscle guarding. The challenge, of course, is access — physical therapy requires appointments, transportation, and often insurance pre-authorization, whereas a pill is immediate.
For acute pain management without anticholinergic effects, over-the-counter nonsteroidal anti-inflammatory drugs like ibuprofen or naproxen have a stronger evidence base than muscle relaxants for most back pain. Heat therapy, gentle movement, and short-term activity modification address muscle spasm without sedation. For older adults with cognitive concerns, a geriatrician or clinical pharmacist can help identify the safest pain management approach that accounts for all existing medications and diagnoses.
Where the Evidence Is Heading
The trajectory of the research is clear and accelerating. The 2024 JAMA review, the 2025 European Spine Journal analysis, and updated positions from organizations like the AAFP all point in the same direction — away from routine muscle relaxant prescribing for back pain. Future clinical guidelines are likely to further restrict recommended indications, particularly for older adults, and deprescribing protocols for muscle relaxants are being developed at several academic medical centers.
For those concerned about brain health, this shift cannot come fast enough. Every month that an older adult remains on an unnecessary anticholinergic medication is a month of avoidable cognitive risk. The conversation between patient and provider should not be whether to try a muscle relaxant — it should be whether there is a compelling, time-limited reason to use one, and when exactly it will be stopped.
Conclusion
Cyclobenzaprine and its fellow muscle relaxants have been part of back pain management for nearly half a century, but the evidence has never supported the way they are actually used — broadly, for too long, and without adequate reassessment. The 2024 JAMA Network Open review of 44 studies found they do not appear beneficial for low back pain beyond the first few days, while 53 percent of patients experience adverse effects including the sedation and cognitive dulling that pose particular dangers to aging brains. For a dementia-focused community, these medications deserve scrutiny every time they appear on a loved one’s medication list.
The actionable takeaway is specific: ask about every muscle relaxant at the next medication review. Find out when it was started, why, and whether the prescribing physician intended it to continue this long. Advocate for deprescribing when the drug has outlived its narrow window of usefulness, and push for physical therapy, movement-based strategies, and non-anticholinergic pain management. Protecting the brain sometimes means questioning the medications that were prescribed with the best of intentions but have quietly become part of the problem.
Frequently Asked Questions
Is cyclobenzaprine safe for older adults with mild cognitive impairment?
The evidence suggests significant caution. Cyclobenzaprine has anticholinergic properties that suppress acetylcholine, a neurotransmitter already diminished in cognitive decline. With 53 percent of patients experiencing adverse effects like drowsiness and dizziness, and no demonstrated long-term benefit for back pain, most geriatric specialists would recommend exploring alternatives first.
How long should someone take a muscle relaxant for back pain?
The Mayo Clinic recommends cyclobenzaprine for short-term use of two to three weeks alongside rest and physical therapy. A meta-analysis in JAMA Internal Medicine found that cyclobenzaprine’s benefit is modest and greatest only in the first four days. If pain persists beyond two to three weeks, a different treatment approach is warranted rather than continuing the medication.
Are all muscle relaxants equally risky?
No. Carisoprodol (Soma) was reclassified as a Schedule IV controlled substance by the DEA in 2012 due to abuse and dependency. When combined with opioids, baclofen carries the highest overdose hazard ratio at 2.52, while carisoprodol has a ratio of 1.64. Cyclobenzaprine has the strongest anticholinergic effects among the commonly prescribed options, making it particularly concerning for cognitive health.
Can stopping a muscle relaxant suddenly cause withdrawal symptoms?
Abrupt discontinuation after prolonged use can cause rebound symptoms including insomnia, nausea, and headache, particularly with carisoprodol. This is why deprescribing should be a structured, gradual process supervised by a physician — not a sudden stop. The fact that withdrawal symptoms occur, however, should not be mistaken for evidence that the drug was still providing therapeutic benefit.
What should I do if my parent’s doctor keeps prescribing a muscle relaxant?
Request a formal medication review, ideally with a geriatrician or clinical pharmacist. Come prepared with specific questions: what is the current indication, has the original condition resolved, and have non-pharmacological alternatives been tried. Reference the 2024 JAMA Network Open review, which recommends deprescribing if pain goals are not being met. If the prescribing physician is not the primary care doctor, ensure all providers are communicating about the medication list.
